Skip to main content
Study of 198 RMD pts, vaccinated 91% JAKi and 80% MTX mono pts were Ab+ for spike protein. Adjusting MTX or JAKi did not significantly alter the immunogenicity (S1 spike Abs). DMARD adjustments w/ COVID-19 VAX may not be needed. https://t.co/ebw172M5I4 https://t.co/vjXqTbuD5t
Dr. John Cush @RheumNow( View Tweet )
May 16, 2022
Acne with JAK Inhibitors JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAKi.https://t.co/ADzaBjgsAN https://t.co/Yydo47UGYl
Dr. John Cush @RheumNow( View Tweet )
May 14, 2022
Early results from the U-ENDURE, Phase 3 RCT of upadacitinib in adult Crohns disease. Pts responding to UPA 45 mg/d were given PBO or UPA (15 or 30 mg). 52 wk UPA achieved CDAI (37% & 48% vs 15% PBO)& endoscopic remission (28% & 40% vs 7%) https://t.co/eo2KtNOUW8 https://t.co/MKnTxVEkth
Dr. John Cush @RheumNow( View Tweet )
May 14, 2022
EADV Dermatology Meeting presents data on the 2 year safety of Deucravacitinib, (TYK2 inhibitor); also showing DEUC is effective in scalp, nail, & palmoplantar PSO. Data from the phase 3 POETYK PSO-1 and PSO-2 trials https://t.co/cFz6XkpA69 https://t.co/ZNJzph6i5N https://t.co/QJZEhzqkY4
Dr. John Cush @RheumNow( View Tweet )
May 13, 2022
PsA,Pod,RNL

RNL 2022: Psoriatic Arthritis Advances

May 11, 2022

Tuesday Nite Rheumatology on 10 May 2022 featured session highlights from RheumNow Live 2022.



This webinar presented exerpts from these lectures along with audience Q & A



  • Psoriatic Arthritis Guidelines Arthur Kavanaugh, MD

  • Drug Targeting in PsA Bruce Kirkham
Read Article
RheumNow Podcast square

What is JAKne? (5.6.2022)

May 06, 2022

Dr. Jack Cush reviews the news, journal reports, FDA actions, new side effects and changing prevalence of Gout.




  1. Gout affects >10 million (4%) in USA, but now w/ more ethnicity, with highest risk in Native Hawaiians (HR 2.21), followed by Black (1.34) and Japanese (1.14);

Read Article
acne

Acne with JAK Inhibitors

May 05, 2022

JAK inhibitors have become enormously popular and while their side effect profile has been delineated and reviewed, little mention is made of acne – an adverse event that may affect up to one-quarter of patients taking JAK inhibitors (JAKi).

Read Article
RA, hands, MCP, deformity

Trends in Rheumatoid Arthritis Disabililty, Despite Biologics

MedPage Today
May 03, 2022

Disability claims in the U.S. related to rheumatoid arthritis (RA) were just as common in 2015 as in 1999, a government researcher found, against expectations that the advent of biologic therapy would have led to a steady decrease.



Over that 17-year period, rates of Medicare

Read Article
FDA%20approved.jpg (keep)

Upadacitinib FDA Approved for Ankylosing Spondylitis

May 02, 2022

Abbvie has announced the US Food and Drug Administration has approved upadacitinib (Rinvoq or UPA) for use in adults with active ankylosing spondylitis, who have not responded or been intolerant of one or more TNF blockers. The recommended dose is 15 mg per day.

Read Article
TNR,controversies,psa

TNR - Controversies in PsA

Apr 20, 2022

Held on April 19, 2022, Tuesday Night Rheumatology: Controversies in PsA, featured a lively and informative panel discussion, moderated by Dr. Jack Cush.



The PsA Expert panelists included:



  • Dr. Dafna Gladman, Toronton

  • Dr. Joseph Merola, Boston

  • Dr. Peter
Read Article
RheumNow Podcast square

Male vs. Female Responders (4.15.2022)

Apr 15, 2022

Dr. Jack Cush reviews the news and journal Reports from the past week on RheumNow.com - including fellowship COVID-19 concerns, the limits of T2T in gout and the real odds of RA remission with your first biologic. 




  1. Downward Effects! Real world data from 22,934 UK #RA pts

Read Article
ICYMI: Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/UOPteZY0g8 https://t.co/Xw3ZSPWeE0
Dr. John Cush @RheumNow( View Tweet )
Apr 10, 2022
RheumNow Podcast square

RheumNow Podcast – What You Do For & What You Do To the Patient (4.8.2022)

Apr 08, 2022

Dr. Jack Cush reviews the news and journal articles from the past week and discusses the use of fibroscan in RA, steroid hip injections in OA and famous quotes from a famous cardiologist.




  1. CorEvitas Registry study of173 Axial #PsA pts showed 6 mos of bDMARD/tsDMARD resulted

Read Article
Deucravacitinib, TYK2 inhib, studied in phase II trial 203 active PsA pts randomised to PBO, or DEUC 6 mg or 12 mg qd. At wk 16 ACR-20 responses were significantly higher with DEUC 6mg (53%, p=0.0134) and 12 mg (63%, p=0.0004) vs PBO. https://t.co/0nvutsXHsI https://t.co/jh43zCbdZx
Dr. John Cush @RheumNow( View Tweet )
Apr 07, 2022
Baricitinib Efficacy in Alopecia Areatahttps://t.co/6jYX5sPW44 https://t.co/Hvalig6U7V
Dr. John Cush @RheumNow( View Tweet )
Mar 31, 2022
Psoriasis Severe legs sara

Differences in Biologic Persistence in Psoriasis and Psoriatic Arthritis

Mar 29, 2022

Administrative claims analysis of biologic use in psoriasis (PsO) and psoriatic arthritis (PsA) in French health insurance databases shows that despite widespread biologic use, overall drug persistence (beyond 3 years) was low for PsO and PsA biologics.

Read Article
alopecia,areata,bald,hairloss

Baricitinib Efficacy in Alopecia Areata

Mar 28, 2022

The NEJM has published the results of the BRAVE-AA1 and BRAVE-AA2 trials, demonstrating that baricitinib is effective at regrowing hair in alopecia areata (AA) patients, thus paving the way for future regulatory approval for this difficult to treat disorder. 



Alopecia areata is an

Read Article
Ask Cush Anything! Have a rheumatology question or case for Dr. Cush? Submit it here and we may feature it on an upcoming podcast. https://t.co/KgPIeScthr https://t.co/nk4re9mlcH
Dr. John Cush @RheumNow( View Tweet )
Mar 25, 2022
CV,risk,MI,heart,cardiac

Stable Low Risk of Acute Coronary Syndrome in RA

Mar 24, 2022

A Nordic multinational collaborative study examined the risk of acute coronary syndrome (ACS) in rheumatoid arthritis and found a less than 2 fold increased risk of ACS patients initiating biologic disease-modifying antirheumatic drugs (bDMARDs) with little risk variation with short-term,

Read Article
@Janetbirdope on drug cycling vs. switching in RA Interesting data showing switching to non-TNFi superior to cycling in TNFi-incomplete responders Most bDMARDs and JAKi have blunted response post-TNFi @RheumNow #RNL2022 https://t.co/Lb3wvHZdzN
Robert B Chao, MD @doctorRBC( View Tweet )
Mar 20, 2022
@Janetbirdope shares her study on real world retention of JAKi vs biologics in #RA #RNL2022 @rheumnow https://t.co/hNxQ8t4LHH
TheDaoIndex @KDAO2011( View Tweet )
Mar 20, 2022
What's unique about the new Tyk2 inhibitor, deucravacitinib, under study in #PSO and #PsA. #RNL2022 https://t.co/J04uJxeX2v
Dr. John Cush @RheumNow( View Tweet )
Mar 20, 2022
RheumNow Podcast square

Consequences of TNF inhibition (3.18.2022)

Mar 18, 2022

This week we're going to talk about the downside of TNF inhibitors, a few interesting observations in gout, and yes, kids do get COVID. We're also going to preview what's coming in April (hint: it's about PsA). This and more as Dr. Jack Cush reviews the news and journal articles from the past

Read Article
RheumNow Podcast square

RheumNow Live is Coming to Town (3.11.2022)

Mar 11, 2022

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.

Read Article
PSA2L.jpg

Psoriatic Arthritis Responds to Tyk2 inhibition with Deucravacitinib

Mar 10, 2022

Deucravacitinib, a selective tyrosine kinase 2 (TYK2) inhibitor, was studied in a phase II trial of active psoriatic arthritis (PsA) patients and shown to be effective and safe.



This double-blind, phase II trial, enrolled 203 patients with active PsA and randomised them to either

Read Article
×